CD28-IN-3 

CD28-IN-3 is a CD28 inhibitor with an IC₅₀ of 7.80 μM and a Kd of 52.45 μM. CD28-IN-3 selectively blocks the CD28-B7 interaction, thereby inhibiting CD28-mediated costimulation. CD28-IN-3 suppresses the production of proinflammatory cytokines IFN-γ, IL-2 and TNF-α. CD28-IN-3 can be used in the research of checkpoint-resistant cancers^[1].

CD28-IN-3 (Compound 22VS) (0-100 μM; 2 h) inhibits the interactions of membrane-bound CD28-CD80 and CD28-CD86 in CHO-K1 cells, with corresponding submicromolar IC₅₀ values of 1.48 μM and 1.39 μM, respectively^[1].
CD28-IN-3 (10-300 μM; 24 h) shows no cytotoxicity against human Jurkat T lymphocytes even at concentrations up to 300 μM following a 24 h incubation^[1].
CD28-IN-3 (0-200 μM; 5 h) inhibits CD28-mediated T cell costimulation in the Jurkat-Raji co-culture system, with an IC₅₀ of 6.96 μM^[1].
CD28-IN-3 (10-50 μM; 48 h) inhibits the release of CD28-dependent proinflammatory cytokines (IFN-γ, IL-2, TNF-α) in a dose-dependent manner in 3D A549 tumor-PBMC co-culture systems and human PBMC-mucosa co-culture systems^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

364.53

C₁₇H₂₄N₄OS₂

850550-70-8

CCC(NC(CSC1=NN=C(S1)NC2=CC=C(C=C2)C(C)C)=O)C

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Upadhyay S, et al. Structure-based virtual screening identifies potent CD28 inhibitors that suppress T cell co-stimulation in cellular and mucosal models. Eur J Med Chem. 2025;300:118194.  [Content Brief]